The Characteristics of Blood Glucose Profile and the Changes of Hormones in PPDM-C Population
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Chronic Pancreatitis, Diabetes. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
The Characteristics of Blood Glucose Profile and the Changes of Endogenous and Exogenous Hormones in Patients with Post-chronic Pancreatitis Diabetes Mellitus
Overview
The purpose of this study was to explore the characteristics of blood glucose spectrum, changes of endocrine/exocrine pancreatic function and the correlation between them in patients with PPDM-C.
Detailed description
The benefits of this study to participants include:
1. It will help to make early diagnosis or risk screening for the potential related risks and concomitant diseases of the disease; 2. Provide necessary suggestions for the treatment and intervention of the disease, or provide useful information for the related research of the disease. 3. We will provide Abbott version h dynamic glucose meter and assessment of internal and external secretion function. The researcher will provide professional endocrine related lifestyle and drug guidance for the subjects according to their CGMS data.
The risks that this study may bring to participants are:
There may be some very small risks in specimen collection, including transient pain, local cyanosis, etc. a few people will have mild dizziness or extremely rare needle infection.
Primary outcome measures
- Blood glucose profile characteristics of patients with PPDM-C [Time frame: From February 2025 to December 2025]
Eligibility criteria
Inclusion criteria
- Male or female Chinese subjects;
- Was ≥ 18 years old when signing the informed consent;
- Patients with complete diagnosis of chronic pancreatitis; ④ Those who voluntarily signed informed consent; ⑤ Those who complete serum samples in multiple centers and put them into storage.
Exclusion criteria
- Patients with impaired glucose tolerance but undiagnosed diabetes;
- Patients with T1DM related autoimmune markers or other types of DM;
- Patients with autoimmune pancreatitis, recurrent acute pancreatitis or acute onset of chronic pancreatitis;
- Patients who underwent pancreatic surgery or related invasive procedures during treatment;
- Previous or current malignant tumor; ⑥ Pregnancy or lactation; ⑦ Suffering from severe heart, liver or kidney dysfunction or malignant disease; ⑧ Failure to sign informed consent for cognitive impairment or other reasons.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Cohort
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT06826729 · 2024SL140